Thrombosis: a major contributor to global disease burden
Related Experiment Video
Updated: Apr 22, 2026

In Vitro Microfluidic Disease Model to Study Whole Blood-Endothelial Interactions and Blood Clot Dynamics in Real-Time
Published on: May 24, 2020
Gary E Raskob1, Pantep Angchaisuksiri2, Alicia N Blanco3
1College of Public Health, University of Oklahoma Health Sciences Center, Oklahoma City, Oklahoma.
Insights
Venous thromboembolism (VTE) significantly burdens global health, causing substantial disability-adjusted life-years lost, especially in hospitalized patients. Further data is needed to inform policy and prevention strategies for this widespread condition.
Area of Science:
- Cardiovascular Medicine
- Public Health
- Epidemiology
Background:
- Thrombosis, including venous thromboembolism (VTE), is a major cause of morbidity and mortality.
- Ischemic heart disease and stroke account for a significant proportion of global deaths.
- Data on the global disease burden of VTE was previously lacking.
Purpose of the Study:
- To systematically review the global disease burden of VTE across different income countries.
- To analyze VTE incidence rates and associated disability-adjusted life-years (DALYs).
- To highlight the impact of VTE in both low- and high-income settings.
Main Methods:
- Systematic literature review on the global disease burden of VTE.
- Analysis of incidence data from various countries (Western Europe, North America, Australia, Argentina, China, Korea).
- Assessment of VTE's contribution to DALYs compared to other hospital-acquired conditions.
Main Results:
- Consistent VTE incidence rates (0.75-2.69 per 1,000) observed in developed nations, increasing with age.
- VTE incidence is lower in Chinese and Korean populations but significant due to aging.
- Hospital-associated VTE is a leading cause of DALYs lost in low- and middle-income countries, and second in high-income countries.
Conclusions:
- Venous thromboembolism (VTE) represents a substantial global health burden across all income levels.
- Hospital-associated VTE is a critical contributor to disability and premature death.
- More comprehensive data on VTE burden is essential for effective health policy and resource allocation, including evaluating preventive measures.
Abstract:
Thrombosis is a common pathology underlying ischemic heart disease, ischemic stroke, and venous thromboembolism (VTE). The Global Burden of Disease Study 2010 (GBD 2010) documented that ischemic heart disease and stroke collectively caused one in four deaths worldwide. GBD 2010 did not report data for VTE as a cause of death and disability. We performed a systematic review of the literature on the global disease burden due to VTE in low-, middle-, and high-income countries. Studies from Western Europe, North America, Australia, and Southern Latin America (Argentina) yielded consistent results with annual incidences ranging from 0.75 to 2.69 per 1,000 individuals in the population. The incidence increased to between 2 and 7 per 1,000 among those 70 years of age or more. Although the incidence is lower in individuals of Chinese and Korean ethnicity, their disease burden is not low because of population aging. VTE associated with hospitalization was the leading cause of disability-adjusted-life-years (DALYs) lost in low- and middle-income countries, and second in high-income countries, responsible for more DALYs lost than nosocomial pneumonia, catheter-related blood stream infections, and adverse drug events. VTE causes a major burden of disease across low-, middle-, and high-income countries. More detailed data on the global burden of VTE should be obtained to inform policy and resource allocation in health systems, and to evaluate if improved utilization of preventive measures will reduce the burden.
Related Concept Videos
Venous Thrombosis I: Introduction
Venous Thrombosis III: Interprofessional Care
Disorders of Hemostasis
Thromboembolic Disorders
Two factors primarily cause thromboembolic conditions.
Pulmonary Embolism I: Introduction
Pulmonary Embolism I: Introduction
Anticoagulant Drugs: Low-Molecular-Weight Heparins

